|Bid||2.04 x 21500|
|Ask||2.10 x 3200|
|Day's Range||1.9800 - 2.1000|
|52 Week Range||1.4900 - 3.5900|
|Beta (3Y Monthly)||2.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
AVEO Oncology (AVEO) today announced that it has entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's IMFINZI® (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with FOTIVDA® (tivozanib), AVEO’s oral, once-daily, potent and highly-selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) in first-line hepatocellular carcinoma (HCC), or liver cancer, in a Phase 1/2 study. AVEO will serve as the study sponsor, with study costs shared equally by both parties and clinical drug supplied by each respective company. “We are thrilled to collaborate with AstraZeneca to explore another tivozanib-immunotherapy combination and look forward to understanding the potential of combining tivozanib with durvalumab in liver cancer,” said Michael Bailey, president and chief executive officer of AVEO.
AVEO Oncology (AVEO) today announced a six-month extension to the interest only period under its existing amended and restated loan and security agreement with Hercules Capital, Inc. (Hercules). The extension was granted as a result of achieving certain predefined requirements under the agreement, including successfully meeting the primary endpoint of the Company’s Phase 3 TIVO-3 study of tivozanib in refractory advanced or metastatic renal cell carcinoma (RCC), by demonstrating a significant improvement in progression free survival. The Company will begin making principal payments on the $20.0 million facility starting on August 1, 2019.
The biotech sector continues to see bearish sentiment and trading action. Small biotech stocks rallied just over 2% on Monday to begin a new trading week, but all those gains were given right back in Tuesday's session.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The SEC accused David Johnston of failing to disclose that the FDA had recommended that Aveo conduct a second late-stage trial of a kidney cancer drug, which was ultimately rejected.
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
New market trends are pushing investors to pay closer attention to the healthcare industry as it has been seen as a safe haven during turbulent times in the broader markets. In fact, according to the "Cognitive Computing and Artificial Intelligence Systems Market in Healthcare" report from ResearchAndMarkets these technologies have gained significant traction. Increased adoption of cognitive and AI platforms can be attributed to their wide application potential across the healthcare industry, including patients and hospitals.
AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com.
AVEO Oncology (AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC). In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with RCC and for adult patients who are vascular endothelial growth factor receptor (VEGFR) and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for RCC.
HENDERSON, NV / ACCESSWIRE / November 14, 2018 / With the sharp declines in biotechnology stocks, with the iShares Nasdaq Biotechnology exchange traded fund (ETF) and SPDR S&P Biotech ETF recently down ...
AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.
AVEO (AVEO) delivered earnings and revenue surprises of 16.67% and 262.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 18 cents. Losses, adjusted for non-recurring costs, were 5 cents per share. The results beat Wall Street expectations. ...
AVEO Oncology today reported financial results for the third quarter ended September 30, 2018 and provided a business update.
AVEO Oncology (AVEO) today announced positive topline results from the primary analysis of the TIVO-3 trial, the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®) to sorafenib in 351 subjects with highly refractory advanced or metastatic renal cell carcinoma (RCC). The trial met its primary endpoint of demonstrating a statistically significant benefit in progression-free survival (PFS). Among these, approximately 26% of patients received checkpoint inhibitor therapy in earlier lines of treatment.
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Oncology (AVEO) and EUSA Pharma today announced the presentation of updated interim results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA®) in combination with intravenous (IV) nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced or metastatic renal cell carcinoma. The results were presented today at European Society of Medical Oncology (ESMO) 2018 Annual Congress, in a poster presentation titled “TiNivo: Tivozanib Combined with Nivolumab: Safety and Efficacy in Patients with Metastatic Renal Cell Carcinoma (mRCC)” (Presentation 878P).
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
AVEO Oncology (AVEO) today announced that updated interim data from the Phase 2 portion of the TiNivo trial of tivozanib and nivolumab (OPDIVO®) in advanced renal cell carcinoma will be presented at the European Society of Medical Oncology (ESMO) 2018 Annual Congress being held October 19-23, 2018 in Munich, Germany. The TiNivo study is a Phase 1b/2 multicenter trial of oral tivozanib (FOTIVDA®) in combination with intravenous nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of metastatic renal cell carcinoma (mRCC). The accepted abstract, which includes results from a poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in January, is available via the ESMO 2018 Annual Congress website.
AVEO Oncology (AVEO) today announced that it has initiated topline analysis of the phase 3 TIVO-3 clinical trial on the unanimous recommendation of the independent TIVO-3 Study Steering Committee, and after notice to the FDA. The TIVO-3 trial is the Company’s randomized, controlled, multi-center, open-label study to compare FOTIVDA® (tivozanib) to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). The Company expects to complete data analysis and report topline results from the study in approximately 6 weeks.
NEW YORK, NY / ACCESSWIRE / September 26, 2018 / U.S. equities were mixed on Tuesday as concerns of a potential trade war linger and investors look forward to details from the upcoming Fed monetary policy ...